Article Text

Download PDFPDF
The Role of Positron Emission Tomography/Computed Tomography in Planning Radiotherapy in Endometrial Cancer
  1. Bryony Simcock, MBBS, BSc, CGO*,
  2. Kailash Narayan, MD*,
  3. Elizabeth Drummond, BAppSc, MSc*,
  4. David Bernshaw, MD*,
  5. Elizabeth Wells and
  6. Rodney J. Hicks*
  1. *Peter MacCallum Cancer Centre, Melbourne, Australia; and
  2. Biostatistics and Computational Biology, Population Health, University of Otago, Christchurch, New Zealand.
  1. Address correspondence and reprint requests to Bryony Simcock, MBBS, BSc, CGO, Department of Obstetrics and Gynaecology, Christchurch Women’s Hospital, Level 3, Private Bag 4710, Christchurch, New Zealand. E-mail: Bryony.simcock{at}


Objective The optimal method of assessing disease distribution in endometrial cancer is widely debated. Knowledge of disease distribution assists in planning adjuvant radiotherapy; in this study we used positron emission tomography/computed tomography (PET/CT) to assess disease distribution before radiotherapy.

Methods Seventy-three consecutive patients referred to the Peter MacCallum Cancer Centre for adjuvant radiotherapy for endometrial cancer, with either high-risk disease after a hysterectomy or recurrent disease, had a PET/CT before treatment. The findings on PET/CT and clinical course were recorded.

Results PET/CT found additional disease in 35% of postoperative patients, changing planned treatment in 31%. In the group with known recurrence, additional disease was found in 72%, changing management in 36%.

Conclusions PET/CT is a valuable tool for planning radiotherapy in endometrial cancer.

  • PET/CT
  • Endometrial cancer
  • Adjuvant radiotherapy
  • High-risk endometrial cancer
  • Radiotherapy planning

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Bryony Simcock is currently affiliated with Christchurch Women’s Hospital Christchurch, New Zealand.

  • The authors declare no conflicts of interest.